CASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma indications. A CASI 80%-owned China subsidiary will invest $11.6 million in Juventas instead of an upfront payment. CASI will make development milestone payments and pay sales royalties, though details were not disclosed. Juventas will continue to develop CNCT19 with CASI’s participation on the program’s steering committee.
Source: China Biotoday